On Demand Activities

Visualizing Progress for TP53 Mutant AML: A Pathology-Guided Journey through Diagnostic Principles and Modern Treatment

0.50 hr(s) | CME , MOC , ABIM , ABPath , CC

Specialty: AML

Therapeutic Area(s): Oncology

Release Date: May 5, 2021

Expiration Date: May 4, 2022

Location: Internet Activity Enduring

In this activity, an expert pathologist discusses the prognostic relevance of TP53 mutations, current diagnostic tools and principles for capturing TP53-mutated acute myeloid leukemia (AML), and new developments with innovative therapy for TP53-mutated AML.

Striking A Balance: Weighing the Benefits and Risks of Treatment With Direct Oral Anticoagulants in Individuals With Nonvalvular Atrial Fibrillation or Venous Thromboembolism

1.00 hr(s) | CME

Specialty: Nonvalvular Atrial Fibrillation

Therapeutic Area(s): Cardiology , Hematology , Oncology , Pulmonology

Release Date: April 21, 2021

Expiration Date: April 20, 2022

Location: Internet Activity Enduring

In this activity, a series of simulations will allow participants to assess patients with NVAF and VTE to better identify barriers to treatment, evaluate the risk of thrombotic events vs risks of bleeding, and choose the right DOAC or other options in anticoagulation therapy for each patient.

Addressing the Unmet Needs of Patients with Moderate-to-Severe Alopecia Areata: A Visual Exploration of Disease Pathogenesis & the Clinical Potential of Novel Therapeutic Options

0.50 hr(s) | CME , MOC , ABIM

Therapeutic Area(s): Dermatology

Release Date: April 8, 2021

Expiration Date: April 7, 2022

Location: Internet Activity Enduring

In this activity, an expert in dermatology discusses contemporary approaches to improve the care of patients with moderate to severe alopecia areata.

Optimizing Care for High-Risk Myeloid Cancers: Interprofessional Team Insights

0.75 hr(s) | CME , NCPD , MOC , ABIM , ABPath , CC

Therapeutic Area(s): Hematology , Oncology

Release Date: April 14, 2021

Expiration Date: April 13, 2022

Location: Internet Activity Enduring

In this CME/MOC/CC/NCPD-accredited activity, a hematologist-oncologist, a pathologist, and a physician assistant team up to discuss a collaborative approach to managing their patients with high-risk myeloid cancers, such as acute myeloid leukemia and myelodysplastic syndrome. Hear how Naval Daver, MD, Sanam Loghavi, MD, and Megan Wiese, PA-C, from the MD Anderson Cancer Center, collaborate on diagnosis, treatment decision-making, safety management, and patient education, with the ultimate goal of providing the best care for their patients.

Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy

0.50 hr(s) | CME

Specialty: acute hepatic porphyria

Therapeutic Area(s): Gastroenterology , Emergency Medicine

Release Date: April 15, 2021

Expiration Date: April 14, 2022

Location: Internet Activity Enduring

In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option.

Addressing the Burden of Polyarticular Juvenile Idiopathic Arthritis (pJIA): A Roadmap to Improving Early Diagnosis and Treatment to Maximize Long-Term Outcomes

0.50 hr(s) | CME , MOC , ABIM

Specialty: Polyarticular Juvenile Idiopathic Arthritis

Therapeutic Area(s): Pediatrics , Rheumatology

Release Date: April 8, 2021

Expiration Date: April 7, 2022

Location: Internet Activity Enduring

In this activity, an expert in pediatric rheumatology discusses contemporary approaches to improve the care of patients with polyarticular juvenile idiopathic arthritis.

Conversations on the New Wave of Innovative Therapy in Follicular Lymphoma: Implications for Personalized Medicine

0.50 hr(s) | CME

Specialty: Follicular Lymphoma

Therapeutic Area(s): Oncology

Release Date: April 5, 2021

Expiration Date: April 4, 2022

Location: Internet Activity Enduring

In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management.

1 2 3 13
Copy link
Powered by Social Snap